AEON Biopharma Announces Topline Results from Phase 2 Trial of ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Episodic Migraine
Figure 1 – Change in Monthly Migraine Days (MMD) (Weeks 21-24) p=0.2844 (150 U vs. Placebo); and p=0.1711 (195 U…